Nektar Therapeutics presents Phase 2b rezpegaldesleukin data from REZOLVE-A and REZOLVE-AD at EADV congress

Nektar Therapeutics presented data from its Phase 2b REZOLVE-A and REZOLVE-AD trials of rezpegaldesleukin at the European Academy of Dermatology and Venereology congress.

Detected & updated continuously · Source: Nebula